Systematic review and meta-analysis of doxycycline efficacy for rectal lymphogranuloma venereum in men who have sex with men.
LGV is caused by Chlamydia trachomatis serovars L1-L3 which, following mucosal inoculation, disseminate via underlying tissue to regional lymph nodes. This infection process contrasts with that of chlamydia infections caused by C. trachomatis serovars A-K, which are limited to the mucosa (5). Prior to the 21st century, LGV was endemic to Southeast Asia, the Caribbean, Latin America, and Africa, where infections mainly involved genital inoculation and ulceration with lymphatic spread, resulting in bubo formation (5.6). More recently, LGV infections among MSM have been largely attributable to the L2b variant of C. trachomatis and have predominantly presented as rectal infections following inoculation of the rectal mucosa (3). Compared with MSM who have rectal infections caused by chlamydia strains unrelated to LGV, MSM who have rectal LGV are more likely to have symptoms of proctitis and more likely to be HIV-positive (7). Symptomatic proctitis is a syndrome commonly seen among MSM attending STI clinics; cases caused by LGV and other sexually acquired pathogens are often clinically indistinguishable (8,9). Exudative proctitis has frequently been observed, by proctoscopy, in patients with rectal LGV (10,11). Asymptomatic rectal LGV also occurs and has accounted for different proportions of LGV cases in various studies (7,12,13).
A comparative study published in 1957 provided early evidence for the efficacy of tetracyclines for reducing bubo duration when used for 14 days (14). Several national and regional guidelines currently recommend doxycycline (100 mg 2x/d for 21 d) as first-line therapy for rectal LGV (5,6,15,16). The deep-seated nature of LGV infection is one rationale for this 3-week duration of treatment (12). In a prospective study using repeated testing to verify response to therapy, rectal chlamydia RNA was detectable for up to 16 days following commencement of doxycycline treatment, adding weight to the need for a longer course of doxycycline for LGV (17). However, several case reports have described doxycycline failing to cure LGV in MSM despite 21 days of therapy, including cases of LGV buboes and rectal LGV (18-21). To provide an evidence base for the use of doxycycline as treatment for rectal LGV infections in MSM, we conducted a systematic review and metaanalysis of studies reporting microbial cure among MSM with rectal LGV treated with 100 mg doxycycline twice daily for 21 days.
Protocol and Registration
This systematic review and meta-analysis was conducted and reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Statement (http://prisma-statement.org/). The study protocol was registered with PROSPRERO (International Prospective Register of Systematic Reviews, http://www.crd.york.ac.uk/PROSPERO/; registration no. CRD42016036038).
Six electronic bibliographic databases (Medline, Embase, PubMed, ClinicalTrials.gov, Cochrane Central Register of Controlled Trials, and the Australian New Zealand Clinical Trials Registry) were searched for studies from 1940 to February 2016. In addition, we hand-searched conference abstracts that were available from the International Society for Sexually Transmitted Diseases Research for 2003-2013 and from the International Union against Sexually Transmitted Infections for 2009-2015; we also searched the reference lists of identified papers. Only abstracts published in English were included in the review. No attempt was made to identify unpublished studies.
We used the following search terms: "lymphogranuloma venereum" or "LGV" or "lymphogranuloma venereum" and "treatment" or "LGV and treatment." Medical subject headings (MeSH) were used where possible. To capture all relevant articles, we did not restrict the search strategy specifically to doxycycline or rectal LGV.
Inclusion and Exclusion Criteria
We searched for any published studies providing data on microbial cure of rectal LGV in MSM. Patients were considered cured if a repeat anal swab sample was negative for C. trachomatis by nucleic acid amplification testing (NAAT) after treatment with 100 mg doxycycline twice daily for 21 days. So that study cure rates could be included in the meta-analysis, we required the following data for study inclusion: 1) the number of MSM with rectal LGV treated with 100 mg doxycycline twice daily for 21 days; 2) the number of these men who had repeat testing for rectal chlamydia infection following this treatment; and 3) the results of repeat testing for rectal chlamydia infection. Studies with bisexual men were included as studies with MSM. For studies in which the 3 data above were not clear from the published papers or abstracts, we contacted authors to directly request the information. If the information was obtained, the studies and their data were included in the meta-analysis. Studies were excluded if 1) cure rates for rectal infection specifically, as distinct from inguinal buboes, could not be obtained; 2) the total sample size of the study was <10; 3) infections were in heterosexual men only; or 4) if different drugs or dosing regimens were used. Conference abstracts were also included if they fulfilled the inclusion criteria.
Data Extraction Process
We extracted the following data from each study: study design treatment administered, sample size, proportion of rectal LGV infections that were symptomatic, the diagnostic method for assessing microbial cure, attrition rate of study subjects, and microbial cure after treatment. One author (C.L.) undertook selection of studies, and another (J.J.O.) checked the selection. Disagreements were resolved by discussion and consultation with a third author (M.C.) until a consensus was reached.
Treatment efficacy for doxycycline, as determined by microbial cure, was calculated by using the number of treated men with a negative repeat test result by NAAT as the numerator and the number of treated men who underwent repeat testing as the denominator. A single C. trachomatis-mgative anal swab sample after treatment was considered confirmation of microbial cure. Likewise, a repeat anal swab test positive for a chlamydia strain genotype not associated with LGV was also considered confirmation of cure but was associated with chlamydia reinfection.
Meta-analysis was applied to calculate the pooled estimates of doxycycline efficacy. We used the P test to estimate the approximate proportion of variability in point estimates attributed to heterogeneity other than that due to chance (22). Random-effects model results were shown if P was >25%, and fixed-effects model results were shown if P was [less than or equal to] 25%.
Assessment of Bias and Quality
Publication bias was not assessed using a funnel plot because <10 studies met the inclusion criteria (23). Two authors (C.L. and J.J.O.) independently assessed within-study bias using evaluation criteria reported elsewhere (24). Any discrepancies were resolved by recourse to a third author (M.C.). Meta-analysis was conducted using STATA version 13 (StataCorp LP, College Station, TX, USA).
Study Selection and Characteristics
We reviewed 93 of 2,037 identified studies; 9 met our inclusion criteria (Figure 1; Table 1). Five studies were presented in published articles (3.17.25-27). and 4 were presented as conference abstracts (28-31). For 6 of these 9 studies, we obtained additional data on rectal microbial cure rates through personal communications so that the studies could be included in our analysis (Table 1) (3,26,28-31). In 1 study, 100 mg doxycycline twice daily for 21 days was used as the comparator group; we used the microbial cure in the doxycycline group in our meta-analysis (31). Of the 9 studies, 4 were prospective (3,17,27,31), 4 were retrospective (26,28-30), and 1 was combined prospective and retrospective (25). All studies used NAAT for retesting after treatment. From these studies, data for a total of 282 MSM with rectal LGV who were retested after treatment with doxycycline were available and included in our meta-analysis. Eight studies reported that >80% of men had rectal symptoms when they sought medical care (3,25-31). All but 2 studies (3,25) reported the average time between treatment and repeat testing. A study by de Vries et al. (17) was the only study that undertook multiple repeat testing over time after doxycycline treatment; for the purposes of our analysis, we used the results from week 3 of the study because some men were given additional courses of doxycycline beyond 21 days. Five studies that reported attrition rates for repeat testing and the percentage of men who had repeat testing ranged from 0 to 65% (17,26,27,30,31).
The microbial cure rates for each of the 9 studies ranged from 95% (95% CI 76%-99%) (29) to 100% (95% CI 88%-100%) (31). Based on these 9 studies, the fixed-effects pooled efficacy was 98.5% (95% CI 96.3%-100%; [I.sup.2] = 0%; p = 0.993) (Figure 2).
We assessed the risk of biases within each of the 9 included studies (Table 2; online Technical Appendix Table, http://wwwnc.cdc.gov/EID/article/22/10/16-0986-Techappl.pdf). Of the 9 studies, 7 recruited patients from STI clinics (3,25-29,31): 8 recruited MSM regardless of whether they had rectal symptoms (3,17,25-28,30,31): and 1 recruited only patients with symptomatic proctitis (29). All studies described in-house methods for LGV identification: 2 used a real-time PCR targeting the polymorphic membrane protein H gene (17,26): 1 used nested PCR and restriction fragment length polymorphism (RFLP) analysis targeting the major outer membrane protein gene (25): 1 used real-time multiplex PCR including LGV (31): 1 used PCR amplification of the outer membrane protein 1 (omp1) gene followed by RFLP analysis (27); 1 used omp1 gene sequencing (29): 1 used real-time polymorphic membrane protein H gene PCR and omp1 gene sequencing (3); 1 used LGV-specific molecular serovar typing (28): and 1 used an in-house assay (30).
Studies differed in the manner in which they dealt with the possibility of LGV reinfection or non-LGV chlamydia as a cause of a positive test result after treatment. Three studies with participants whose repeat test results were positive reported that reinfection could have contributed to these results (28-30). Six of the studies conducted genotyping of positive repeat chlamydia specimens (17,26,27,29-31). Two of these studies reported genotyping results: Fosclii et al. (27) reported that 1 patient had a non-LGV serovar on repeat testing, indicating chlamydia reinfection, and Bissessor et al. (29) demonstrated an LGV-associated serovar in a sample from a man who had unprotected sexual intercourse after treatment, making it impossible to determine whether the infection was due to treatment failure or reinfection. None of the studies reported the application of stringent criteria or algorithms, such as an algorithm based on a combination of sexual reexposure and chlamydia genotyping (32), to distinguish treatment failure from reinfection. All but 1 study based microbial cure on a single repeat test.
None of the studies discussed compliance with the full course of doxycycline or the concurrent use of other antimicrobial drugs, both of which could influence treatment outcomes. Three studies reported the authors' conflicts of interest and funding sources (3,17,27). Through the review process, no randomized controlled trials comparing doxycycline with other treatments were identified.
Our meta-analysis found a pooled treatment efficacy of 98.5% (96.3%-100%; [I.sup.2] = 0%) for 100 mg doxycycline twice daily for 21 days for the treatment of rectal LGV infections inMSM. This result supports the recommendation that doxycycline be used at this dosage and duration for the treatment of rectal LGV in MSM, including MSM who are HIV-positive. Several guidelines, including those from Europe, the United Kingdom, and the United States, recommend doxycycline at this dosage and duration as first-line therapy for the treatment of LGV (5,6,15). The results of our meta-analysis provide a high degree of precision to support the continuation of this recommendation.
Although rectal infections with LGV-associated variants of C. trachomatis have been concentrated among MSM, rectal chlamydia infections in MSM are still, overall, more likely to be caused by other chlamydia serovars. Infections with these other serovars have generally been treated with 100 mg doxycycline twice daily for 7 days, which has been shown from meta-analysis (33) to have a pooled efficacy of 99.6%. The efficacy of azithromycin (1 g) for rectal chlamydia infection has been questioned, and randomized trials comparing this with doxycycline for rectal chlamydia are needed. In a prospective study of rectal LGV treatment, 100 mg doxycycline twice daily for 7 days achieved a negative repeat chlamydia test result for only 15 (88%) of 17 MSM (17). Persistent rectal LGV infection despite 10 days of doxycycline treatment has also been reported (18). These reports underscore the value of genotyping positive rectal chlamydia specimens from MSM because the identification of LGV-associated variants will indicate the need for a longer course of doxycycline to ensure cure.
Although our meta-analysis showed that most rectal LGV infections were cured with a 21-day course of doxycycline, clinical failures have been reported with this regimen. In a case from France, an HIV-negative man with LGV proctitis and inguinal lymphadenopathy from the L2 serovar experienced clinical antimicrobial drug treatment failure even though doxycycline treatment was extended beyond 3 weeks. He subsequently achieved clinical resolution with moxifloxacin (18). In a report from Portugal, 2 HIV-positive MSM with rectal LGV from the L2b variant (1 with inguinal lymphadenopathy and the other with fever) did not clinically respond after 3 weeks' treatment with doxycycline (19). In a case from Spain a man with L2 serovar-associated LGV proctitis and inguinal lymphadenopathy received 200 mg doxycycline daily for 21 days, resulting in improved rectal symptoms, but progression of the lymphadenopathy required azithromycin followed by moxifloxacin to achieve clinical cure (20). There have also been reports of LGV buboes in MSM that have not resolved clinically after treatment with doxycycline for 21 days. In some cases, abscess formation and rupture with sinus formation have occurred despite this course of treatment (21,34). These reports suggest that in some cases of more clinically severe or extensive rectal LGV infection 3 weeks' treatment with doxycycline may not be sufficient for clinical and microbial cure. When abscesses are present, treatment failure might reflect poor penetration of antimicrobial drugs. Several national guidelines recommend that LGV infections be clinically observed until completely resolved and that routine test of cure is not necessary if a 21-day course of doxycycline has been completed (5,6 J5). Our study findings support these recommendations.
Cases of rectal LGV among MSM have mainly been attributable to C. trachomatis serovars L2b and L2. Cocirculation of these 2 serovars among MSM in Spain has been shown with distinct clinical manifestations: LGV cases with rectal bleeding and pain have been associated with serovar L2b more than with L2 (3). Previous studies have, however, reported failure of doxycycline treatment in patients infected with the L2 serovar (18 JO). Recently, a new LGV strain, L2c, a recombination of L2 and D strains, has been identified and may be associated with more severe infection (35). However, C. trachomatis serovar L, compared with serovars D-K, has no additional genes that determine disease outcome (3(5,37). Further research is required to define the determinants of LGV invasiveness and pathogenesis (37).
Several points should be considered when interpreting the results of our study. We identified only 9 studies that specifically reported microbial cure rates for MSM with rectal LGV, 4 of which were conference abstracts rather than published papers. The overall pooled efficacy of doxycycline was based on results for a total of 282 men. Although this combined number of cases is limited, the pooling together of otherwise small, individual studies provides a more precise estimate of doxycycline efficacy with tighter CIs than was previously available for each of the separate component studies (Table 1). Only 4 studies were prospective, and several were retrospective studies. We did not identify any randomized controlled trials. We identified considerable limitations in the quality of studies. The studies showed considerable variation in the timing of repeat testing after doxycycline, and only 1 study undertook repeat testing on more than 1 occasion (17). A single negative repeat test could, in theory, miss ongoing infection if organism shedding is intermittent and thus could lead to an overestimation of treatment efficacy (38). Conversely, a positive repeat test could indicate reinfection with LGV or another chlamydia strain rather than treatment failure, leading to an underestimation of treatment efficacy. None of the studies reported criteria or algorithms, as described previously (32), to distinguish treatment failure from reinfection based on sexual reexposure and chlamydia genotyping. Future randomized trials aimed at determining the efficacy of alternative antimicrobial drugs for the treatment of LGV are warranted and should include carefully considered algorithms that distinguish treatment failure from reinfection.
Despite these caveats, our study demonstrated a high microbial cure rate for 100 mg doxycycline twice daily for 21 days for the treatment of rectal LGV in MSM. The data support doxycycline at this dosage and duration as first-line therapy for rectal LGV.
Author affiliations: Mahidol University, Bangkok, Thailand (C. Leeyaphan); Alfred Health, Melbourne, Victoria, Australia (C. Leeyaphan, J.J. Ong, E.P.F. Chow, M. Bissessor, C.K. Fairley, M. Chen); Monash University, Melbourne (J.J. Ong, E.P.F. Chow, C.K. Fairley, M. Chen); University of Melbourne, Melbourne (F.Y.S. Kong, J.S. Hocking)
We thank Stephen P. Higgins, Anna Garner Louise, Juan-Carlos Galan, Sanjeeva Pallawela, Samantha Hill, and Jose Luis Blanco Are valo for additional data.
E.P.F.C. and J.J.O. are supported by the Early Career Fellowship from the Australian National Health and Medical Research Council (nos. 1091226 and 1104781, respectively).
Dr. Leeyaphan, an instructor in the Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, in Bangkok, Thailand, undertook research for this study during her position as Research Fellow at the Melbourne Sexual Health Centre, Alfred Health, in Melbourne, Australia. Her primary research interests are the epidemiology and dermatologie manifestations of sexually transmissible infections.
(1.) Macdonald N. Sullivan AK. French P. White JA. Dean G. Smith A, et al. Risk factors for rectal lymphogranuloma venereum in gay men: results of a multicentre case-control study in the U.K. Sex Transm Infect. 2014:90:262-8. http://dx.doi.org/10.1136/ sextrans-2013-051404
(2.) Hughes G, Alexander S, Simms I, Conti S, Ward H, Powers C, et al. Lymphogranuloma venereum diagnoses among men who have sex with men in the U.K.: interpreting a cross-sectional study using an epidemic phase-specific framework. Sex Transm Infect. 2013:89:542-7. http://dx.doi.org/10.1136/sextrans-2013-051051
(3.) Rodriguez-Dominguez M, Puerta T, Menendez B, Gonzalez-Alba JM, Rodriguez C, Hellin T, et al. Clinical and epidemiological characterization of a lymphogranuloma venereum outbreak in Madrid, Spain: co-circulation of two variants. Clin Microbiol Infect. 2014:20:219-25. http://dx.doi.org/10.1111/1469-0691.12256
(4.) Haar K, Dudareva-Vizule S, Wisplinghoff H, Wisplinghoff F, Sailer A, Jansen K, et al. Lymphogranuloma venereum in men screened for pharyngeal and rectal infection, Germany. Emerg Infect Dis. 2013:19:488-92. http://dx.doi.org/10.3201/eid1903.121028
(5.) de Vries HJ, Zingoni A, Kreuter A, Moi H, White JA; European Branch of the International Union against Sexually Transmitted Infections; European Academy of Dermatology and Venereology; European Dermatology Forum; European Society of Clinical Microbiology and Infectious Diseases; Union of European Medical Specialists; European Centre for Disease Prevention and Control; European Office of the World Health Organization. 2013 European guideline on the management of lymphogranuloma venereum. J Eur Acad Dermatol Venereol. 2015;29:1-6. http://dx.doi.org/10.1111/jdv.12461
(6.) White J, O'Farrell N, Daniels D; British Association for Sexual Health and HIV. 2013 LTK National Guideline for the management of lymphogranuloma venereum: Clinical Effectiveness Group of the British Association for Sexual Health and HIV (CEG/BASHH) Guideline development group. Int J STD AIDS. 2013;24:593-601. http://dx.doi.org/10.1177/0956462413482811
(7.) Saxon C, Hughes G, Ison C. Asymptomatic lymphogranuloma venereum in men who have sex with men, United Kingdom. Emerg Infect Dis. 2016;22:112-6. http://dx.doi.org/10.3201/ EID2201.141867
(8.) Bissessor M. Tabrizi SN. Bradshaw CS. Fairley CK. Hocking JS. Garland SM, et al. The contribution of Mycoplasma genitalium to the aetiology of sexually acquired infectious proctitis in men who have sex with men. Clin Microbiol Infect. 2016;22:260-5. http://dx.doi.org/10.1016/j.cmi.2015.11.016
(9.) Bissessor M, Fairley CK, Read T, Denham I, Bradshaw C, Chen M. The etiology of infectious proctitis in men who have sex with men differs according to HIV status. Sex Transm Dis. 2013;40:768-70. http://dx.doi.org/10.1097/OLQ.0000000000000022
(10.) Van der Bij AK, Spaargaren J, Morre SA, Fennema HS, Mindel A, Coutinho RA, et al. Diagnostic and clinical implications of anorectal lymphogranuloma venereum in men who have sex with men: a retrospective case-control study. Clin Infect Dis. 2006;42:186-94. http://dx.doi.org/10.1086/498904
(11.) Pallawela SN. Sullivan AK. Macdonald N. French P. White J. Dean G, et al. Clinical predictors of rectal lymphogranuloma venereum infection: results from a multicentre case-control study in the U.K. Sex Transm Infect. 2014;90:269-74. http://dx.doi.org/10.1136/sextrans-2013-051401
(12.) Stoner BP, Cohen SE. Lymphogranuloma venereum 2015: clinical presentation, diagnosis, and treatment. Clin Infect Dis. 2015;61:S865-73. http://dx.doi.org/10.1093/cid/civ756
(13.) de Vrieze NH, de Vries HJ. Lymphogranuloma venereum among men who have sex with men. An epidemiological and clinical review. Expert Rev Anti Infect Ther. 2014;12:697-704. http://dx.doi.org/10.1586/14787210.2014.901169
(14.) Greaves AB. Hilleman MR. Taggart SR. Bankhead AB. Feld M. Chemotherapy in bubonic lymphogranuloma venereum: a clinical and serological evaluation. Bull World Health Organ. 1957;16:277-89.
(15.) Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1-137.
(16.) McLean CA, Stoner BP, Workowski KA. Treatment of lymphogranuloma venereum. Clin Infect Dis. 2007;44:S 147-52. http://dx.doi.org/10.1086/511427
(17.) de Vries HJC, Smelov V, Middelburg JG, Pleijster J, Speksnijder AG, Morre SA. Delayed microbial cure of lymphogranuloma venereum proctitis with doxycycline treatment. Clin Infect Dis. 2009;48:e536. http://dx.doi.org/10.1086/597011
(18.) Mechai F, de Barbeyrac B, Aoun O, Merens A, Imbert P, Rapp C. Doxycycline failure in lymphogranuloma venereum. Sex Transm Infect. 2010;86:278-9. http://dx.doi.org/10.1136/ sti.2009.042093
(19.) Castro R, Baptista T, Vale A, Nunes H, Prieto E, Araujo C, et al. Lymphogranuloma venereum serovar L2b in Portugal. Int J STD AIDS. 2010;21:265-6. http://dx.doi.org/10.1258/ijsa.2009.009134
(20.) Vall-Mayans M, Isaksson J, Caballero E, Salles B, Herrmann B. Bubonic lymphogranuloma venereum with multidrug treatment failure. Int J STD AIDS. 2014;25:306-8. http://dx.doi.org/10.1177/0956462413501158
(21.) Oud EV. de Vrieze NH. de Meij A, de Vries HJ. Pitfalls in the diagnosis and management of inguinal lymphogranuloma venereum: important lessons from a case series. Sex Transm Infect. 2014;90:279-82. http://dx.doi.org/10.1136/sextrans-2013-051427
(22.) Higgins JP, Thompson SG, Deeks JJ, Altanan DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. http://dx.doi.org/10.1136/bmj.327.7414.557
(23.) Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. http://dx.doi.org/10.1136/bmj.d4002
(24.) Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol. 2007;36:666-76. http://dx.doi.org/10.1093/ije/dym018
(25.) Waalboer R, van der Snoek EM, van der Meijden WI, Mulder PG, Ossewaarde JM. Analysis of rectal Chlamydia trachomatis serovar distribution including L2 (lymphogranuloma venereum) at the Erasmus MC STI clinic, Rotterdam. Sex Transm Infect. 2006;82:207-11. http://dx.doi.org/10.1136/ sti.2005.018580
(26.) Hill SC, Hodson L, Smith A. An audit on the management of lymphogranuloma venereum in a sexual health clinic in London, UK. Int J STD AIDS. 2010;21:772-6. http://dx.doi.org/10.1258/ ijsa.2010.010329
(27.) Foschi C, Marangoni A, D'Antuono A, Nardini P, Compri M, Bellavista S, et al. Prevalence and predictors of lymphogranuloma venereum in a high risk population attending a STD outpatients clinic in Italy. BMC Res Notes. 2014;7:225. http://dx.doi.org/10.1186/1756-0500-7-225
(28.) Pallawela S, Elgalib A, Almeida M, Aman T, Alexander S, Tong CYW, et al. Three weeks of doxycycline is an effective treatment for rectal lymphogranuloma venereum. HIV Med. 2010;ll(Suppl 1):75-6.
(29.) Bissessor M. P1-S2.39: characteristics of lymphogranuloma venereum (LGV) infection among homosexual men in Melbourne. Sex Transm Infect. 2011;87:A139. http://dx.doi.org/10.1136/sextrans-2011-050108.96
(30.) Vas A, Leighton J, Saxon C, Lebar D, Stott C, Ahmad S, et al. Audit of the clinical management of lymphogranuloma venereum in three inner-city genitourinary medicine clinics. Int J STD AIDS. 2013;24(Suppl 5):30.
(31.) Blanco JL, Fuertes I, Bosch J, Gonzalez A, Vergara A, Camp R, et al. Effective treatment of lymphogranuloma venereum (LGV) with lg azithromycin administered weekly for 3 weeks in an HIV-infected population [CROI abstract 845], Top Antivir Med. 2015;23(e-1):384.
(32.) Batteiger BE. Tu W. Ofner S. Van Der Pol B. Stothard DR. Orr DP, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis. 2010;201:42-51. http://dx.doi.org/10.1086/648734
(33.) Kong FY. Tabrizi SN. Fairley CK. Vodstrcil LA. Huston WM. Chen M, et al. The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis. J Antimicrob Chemother. 2015;70:1290-7. http://dx.doi.org/10.1093/jac/dku574
(34.) Chen MY, Read TRH, Leslie DE, Bissessor M. A couplet: a case of anal ulceration and another of inguinal swelling. Med J Aust. 2011;195:47-8.
(35.) Somboonna N, Wan R, Ojcius DM, Pettengill MA, Joseph SJ, Chang A, et al. Hypervirulent Chlamydia trachomatis clinical strain is a recombinant between lymphogranuloma venereum (L(2)) and D lineages. MBio. 2011;2:e00045-11.
(36.) Harris SR. Clarke IN. Seth-Smith HMB, Solomon AW. Cutcliffe LT, Marsh P, et al. Whole-genome analysis of diverse Chlamydia trachomatis strains identifies phylogenetic relationships masked by current clinical typing. Nat Genet. 2012;44:413-9. http://dx.doi.org/10.1038/ng.2214
(37.) de Vries HJC. Schim Van Der Loeff MF. Braisten SM. High-resolution typing of Chlamydia trachomatis: epidemiological and clinical uses. Curr Opin Infect Dis. 2015;28:61-71. http://dx.doi.org/10.1097/QCO.0000000000000129
(38.) Dukers-Muijrers NH. Speksnijder AG Morre SA. Wolffs PF. van der Sande MA, Brink AA, et al. Detection of anorectal and cervicovaginal Chlamydia trachomatis infections following azithromycin treatment: prospective cohort study with multiple time-sequential measures of rRNA, DNA, quantitative load and symptoms. PLoS ONE. 2013;8:e81236. http://dx.doi.org/10.1371/ journal.pone.0081236
Address for correspondence: Marcus Chen, Central Clinical School Monash University, Melbourne Sexual Health Centre, 580 Swanston St, Carlton, VIC 3053, Australia; email: email@example.com
Table 1. Studies from 2006 to 2015 reporting the efficacy of 100 mg doxycycline twice daily for 21 days for the treatment of rectal LGV in men who have sex with men * Ref. Study Serovar No. men tested No. No. HIV- type positive and symptomatic/ positive/ treated for no. total no. total LGV/no. (%) (%) retested after treatment (25) RS/PS L2 21/21 18/21 (86) 13/21 (62) (17) PS L 20/17 NS NS (26) RS L 55/19 59/63 (94) 52/63 (82) (28) RS L 70/70H 80/99(81) 78/99 (79) (29) RS L2b 20/20# 20/20 (100) 18/25 (72) (30) RS L 80/43 71/83 (85) 69/83 (83) (27) PS L2 13/13 13/13(100) 9/13(69) (3) PS L2, L2b 53/53 73/82 (89) 66/82 (80) ([section] [section]) (31) PS L 28/27 28/28 (100) 27/28 (96) Ref. Method for Time from No. negative retesting treatment repeat test to results/no. retesting repeat tests (% negative; 95% CI) (25) Cobas Amplicor NS 21/21 (100; 85-100) Analyzer ([dagger]) (17) Cobas Amplicor 3 wk 17/17(100; 82-100) Analyzer ([dagger]) (26) BD ProbeTec ET System 3 mo 19/19(100; 83-100) ([double ([section]) dagger]) (28) BD ProbeTec ET System [less 68/69 (99; 92-100) ([double dagger]) than or ([paragraph]) equal to] 6 mo (29) BD ProbeTec ET System 3 mo 19/20 (95; 76-99) (#) ([double dagger]) (30) APTIMA Combo 2 assay ** 6 wk 42/43 (97; 88-100) ([dagger][dagger]) (27) Versant CT/GC DNA 1.0 3 mo 13/13(100; 77-100) assay ([double dagger] [double dagger]) (3) Abbott RealTime CT/NG NS 51/53 (96; 87-99) assay ([paragraph] ([section][section]) [paragraph]), BD ProbeTec ET System ([double dagger]) (31) Real-time multiplex PCR 3 wk 27/27 (100; 88-100) (##) * LGV, lymphogranuloma venereum; NS, not specified; PS, prospective; ref., reference; RS, retrospective; RS/PS, retrospective and prospective. ([dagger]) Roche, Basel, Switzerland. ([double dagger]) Becton Dickinson Microbiology Systems, Sparks, MD, USA. ([section]) S.C. Hill, St. Mary's Hospital, London, UK, pers. comm., 2016 Apr 28. ([paragraph]) Seventy men treated for rectal LGV underwent repeat testing; 1 had an equivocal result and was excluded from further analyses (S. Pallawela, Royal Berkshire Hospital, Reading, UK, pers. comm., 2016 Apr 28). (#) M. Bissessor, Melbourne Sexual Health Centre, Carlton, Victoria, Australia, pers. comm., 2016 Apr 1. ** Gen-Probe Inc., San Diego, CA, USA. ([dagger][dagger]) A. Garner, Stockport NHS Foundation Trust, Stockport, UK, pers. comm., 2016 May 26. ([double dagger][double dagger]) Siemens Healthcare Diagnostics, Terrytown, NY, USA, ([section][section]) J.C. Galan, Hospital Ramon y Cajal, Madrid, Spain, pers. comm., 2016 May 16. ([paragraph][paragraph])Abbott Laboratories, Des Plaines, IL, USA (##) J.L. Blanco, University of Barcelona, Barcelona, Spain, pers. comm., 2016 May 10. Table 2. Summary of risk of bias in studies from 2006 to 2015 included in a systematic review and meta-analysis of the efficacy of doxycycline for rectal lymphogranuloma venereum in men who have sex with men * Method for Methods for Design-specific selection of measuring exposure sources of bias, Ref. participants and outcome excluding variables confounding (25) + + NR (17) + + + (26) + + ++ (28) + + ++ (29) + + ++ (30) + + ++ (27) + + ++ (3) + + NR (31) + + ++ Method to control Statistical Conflict of Ref. confounding methods interest (25) NR + NR (17) NR + + (26) NR + NR (28) NR + NR (29) NR + NR (30) NR + NR (27) NR + + (3) NR + + (31) NR + NR * NR, not reported; ref., reference; +, low risk of bias; ++, moderate risk of bias; +++, high risk of bias. Figure 2. Efficacy of doxycycline (100 mg 2x/d for 21 d) for treatment of rectal lymphogranuloma venereum infection in men who have sex with men. I-V, inverse-variance (fixed) method; D+L, DerSimonian and Laird (random-effects) method; [I.sup.2], test for heterogeneity. Reference or Year of Efficacy (95% CI) Weight, % analysis publication method (26) 2006 1.00 (0.84-1.00) 7.91 (17) 2009 1.00 (0.80-1.00) 5.40 (27) 2010 1.00(0.82-1.00) 6.59 (29) 2010 0.99 (0.92-1.00) 33.96 (30) 2011 0.95 (0.75-1.00) 3.35 (32) 2013 0.98 (0.88-1.11) 13.73 (28) 2014 1.00 (0.75-1.00) 3.36 (3) 2014 0.96 (0.87-1.00) 13.11 (32) 2015 1.00 (0.87-1.00) 12.59 I-V overal 0.99 (0.96-1.00) 100.00 ([I.sup.2] = 0.0%, p = 0.993) D+L overall 0.99 (0.96-1.00)
Please note: Some tables or figures were omitted from this article.
|Printer friendly Cite/link Email Feedback|
|Author:||Leeyaphan, Charussri; Ong, Jason J.; Chow, Eric P.F.; Kong, Fabian Y.S.; Hocking, Jane S.; Bissessor|
|Publication:||Emerging Infectious Diseases|
|Date:||Oct 1, 2016|
|Previous Article:||Ebola virus disease in children, Sierra Leone, 2014-2015.|
|Next Article:||Increase in meningococcal serogroup W disease, Victoria, Australia, 2013- 2015.|